Results 31 to 40 of about 590,194 (288)

Meningococcal vaccination in pregnancy [PDF]

Human Vaccines & Immunotherapeutics, 2018
Invasive meningococcal disease causes meningitis and septicemia worldwide with highest rates of disease occurring in children
Manish Sadarangani, Manish Sadarangani, Bahaa Abu Raya   +2 more
openaire   +4 more sources

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age

Human Vaccines & Immunotherapeutics, 2022
Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence ...
Gary S. Marshall, Stephen I. Pelton, Corwin A. Robertson, Philipp Oster   +3 more
doaj   +1 more source

Development of group B meningococcal vaccine: a progress review

Zhongguo gonggong weisheng, 2022
Epidemic cerebrospinal meningitis is a respiratory infectious disease caused by Neisseria meningitidis, most commonly manifesting as meningitis and septicaemia.
Wei ZHAO, Shuang BAI, Yan-li KANG
doaj   +1 more source

An overview of the meningococcal disease and impact of the quadrivalent meningococcal conjugate vaccine [PDF]

Novel Research in Microbiology Journal, 2021
Meningitis is an inflammation of the meninges, which are the three membranes that cover the brain and the spinal cord; which occurs when the fluid surrounding the meninges becomes infected.
Asmaa Alrobai, Jehan Alrahimi, Sahar El Hadad   +2 more
doaj   +1 more source

Safety of Combination of a Tetravalent Meningococcal Conjugate Vaccine Against Serogroups A, C, Y, W-135 With Other Vaccine Preparations: a Prospective Study of a Series of Cases Among Healthy Children and Children With Various Health Abnormalities

Вопросы современной педиатрии, 2017
Meningococcal infection is an acute disease caused by Neisseria meningitidis, which proceeds with a diverse clinical aspect from nasopharyngitis to meningococcal meningitis and meningococcemia.
Leyla S. Namazova-Baranova, Daria A. Novikova, Marina V. Fedoseenko, Anna G. Gaivoronskaya, Natalia E. Tkachenko, Tatiana A. Kaljuzhnaya, Firuza Ch. Shakhtakhtinskaya, Marika I. Broeva   +7 more
doaj   +1 more source

Meningococcal Vaccines: Challenges and Prospects [PDF]

Vaccines, 2020
Neisseria meningitidis is a gram-negative bacterium that causes a severe acute infection, called the meningococcal disease [...]
Priyal Bagwe, Lotika Bajaj, Rikhav Gala, Susu M. Zughaier, Mohammad N. Uddin, Martin J. D’Souza   +5 more
openaire   +5 more sources

Recommendations for the use of meningococcal vaccines in South Africa

Southern African Journal of Infectious Diseases, 2017
Background: Although meningococcal disease (MD) incidence in South Africa is low, Neisseria meningitidis (NM) causes severe disease that is often life-threatening and can cause long-term disabilities.
Susan Meiring, Gregory Hussey, Prakash Jeena, Salim Parker, Anne von Gottberg   +4 more
doaj   +1 more source

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

PLoS ONE, 2020
IntroductionEculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk.
Catherine H Bozio, Cheryl Isenhour, Lucy A McNamara   +2 more
doaj   +1 more source

Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study

Vaccines, 2018
Gonorrhea is a major global public health problem with emergence of multiple drug-resistant strains with no effective vaccine. This retrospective cohort study aimed to estimate the effectiveness of the New Zealand meningococcal B vaccine against ...
J. Paynter, F. Goodyear-Smith, J. Morgan, P. Saxton, S. Black, H. Petousis-Harris   +5 more
semanticscholar   +1 more source

Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)

Vaccines, 2020
Background: A few years after the introduction in Italy of a four-component anti-meningococcal B vaccine (4CMenB), we evaluated the effectiveness and impact of vaccination in two regions using different schedules (2, 4, 6, 12 months in Tuscany vs.
C. Azzari, M. Moriondo, F. Nieddu, V. Guarnieri, L. Lodi, C. Canessa, G. Indolfi, M. Giovannini, G. Napoletano, F. Russo, T. Baldovin, S. Cocchio, S. Ricci, V. Baldo   +13 more
semanticscholar   +1 more source